Light chain amyloidosis - Current findings and future prospects

Elizabeth M. Baden, Laura A. Sikkink, Marina Ramirez-Alvarado

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Systemic light chain amyloidosis (AL) is one of several protein misfolding diseases and is characterized by extracellular deposition of immunoglobulin light chains in the form of amyloid fibrils [1]. Immunoglobulin (Ig) proteins consist of two light chains (LCs) and two heavy chains (HCs) that ordinarily form a heterotetramer which is secreted by a plasma cell. In AL, however, a monoclonal plasma cell population produces an abundance of a pathogenic LC protein. In this case, not all of the LCs pair with the HCs, and free LCs are secreted into circulation. The LC-HC dimer is very stable, and losing this interaction may result in an unstable LC protein [2]. Additionally, somatic mutations are thought to cause amyloidogenic proteins to be less stable compared to non-amyloidogenic proteins [3-5], leading to protein misfolding and amyloid fibril formation. The amyloid fibrils cause tissue damage and cell death, leading to patient death within 12-18 months if left untreated [6]. Current therapies are harsh and not curative, including chemotherapy and autologous stem cell transplants. Studies of protein pathogenesis and fibril formation mechanisms may lead to better therapies with an improved outlook for patient survival. Much has been done to determine the molecular factors that make a particular LC protein amyloidogenic and to elucidate the mechanism of amyloid fibril formation. Anthony Fink's work, particularly with discerning the role of intermediates in the fibril formation pathway, has made a remarkable impact in the field of amyloidosis research. This review provides a general overview of the current state of AL research and also attempts to capture the most recent ideas and knowledge generated from the Fink laboratory.

Original languageEnglish (US)
Pages (from-to)500-508
Number of pages9
JournalCurrent Protein and Peptide Science
Volume10
Issue number5
DOIs
StatePublished - 2009

Fingerprint

Amyloidosis
Light
Amyloid
Amyloidogenic Proteins
Proteins
Plasma Cells
Proteostasis Deficiencies
Immunoglobulin Light Chains
Plasmas
Transplants
Chemotherapy
Cell death
Stem cells
Research
Dimers
Immunoglobulins
Cell Death
Stem Cells
Cells
Tissue

Keywords

  • Amyloid
  • Fibril formation
  • Immunoglobulin light chain
  • Light chain amyloidosis
  • Protein misfolding

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Light chain amyloidosis - Current findings and future prospects. / Baden, Elizabeth M.; Sikkink, Laura A.; Ramirez-Alvarado, Marina.

In: Current Protein and Peptide Science, Vol. 10, No. 5, 2009, p. 500-508.

Research output: Contribution to journalArticle

Baden, Elizabeth M. ; Sikkink, Laura A. ; Ramirez-Alvarado, Marina. / Light chain amyloidosis - Current findings and future prospects. In: Current Protein and Peptide Science. 2009 ; Vol. 10, No. 5. pp. 500-508.
@article{30d82328290f4987963027037db41140,
title = "Light chain amyloidosis - Current findings and future prospects",
abstract = "Systemic light chain amyloidosis (AL) is one of several protein misfolding diseases and is characterized by extracellular deposition of immunoglobulin light chains in the form of amyloid fibrils [1]. Immunoglobulin (Ig) proteins consist of two light chains (LCs) and two heavy chains (HCs) that ordinarily form a heterotetramer which is secreted by a plasma cell. In AL, however, a monoclonal plasma cell population produces an abundance of a pathogenic LC protein. In this case, not all of the LCs pair with the HCs, and free LCs are secreted into circulation. The LC-HC dimer is very stable, and losing this interaction may result in an unstable LC protein [2]. Additionally, somatic mutations are thought to cause amyloidogenic proteins to be less stable compared to non-amyloidogenic proteins [3-5], leading to protein misfolding and amyloid fibril formation. The amyloid fibrils cause tissue damage and cell death, leading to patient death within 12-18 months if left untreated [6]. Current therapies are harsh and not curative, including chemotherapy and autologous stem cell transplants. Studies of protein pathogenesis and fibril formation mechanisms may lead to better therapies with an improved outlook for patient survival. Much has been done to determine the molecular factors that make a particular LC protein amyloidogenic and to elucidate the mechanism of amyloid fibril formation. Anthony Fink's work, particularly with discerning the role of intermediates in the fibril formation pathway, has made a remarkable impact in the field of amyloidosis research. This review provides a general overview of the current state of AL research and also attempts to capture the most recent ideas and knowledge generated from the Fink laboratory.",
keywords = "Amyloid, Fibril formation, Immunoglobulin light chain, Light chain amyloidosis, Protein misfolding",
author = "Baden, {Elizabeth M.} and Sikkink, {Laura A.} and Marina Ramirez-Alvarado",
year = "2009",
doi = "10.2174/138920309789351949",
language = "English (US)",
volume = "10",
pages = "500--508",
journal = "Current Protein and Peptide Science",
issn = "1389-2037",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Light chain amyloidosis - Current findings and future prospects

AU - Baden, Elizabeth M.

AU - Sikkink, Laura A.

AU - Ramirez-Alvarado, Marina

PY - 2009

Y1 - 2009

N2 - Systemic light chain amyloidosis (AL) is one of several protein misfolding diseases and is characterized by extracellular deposition of immunoglobulin light chains in the form of amyloid fibrils [1]. Immunoglobulin (Ig) proteins consist of two light chains (LCs) and two heavy chains (HCs) that ordinarily form a heterotetramer which is secreted by a plasma cell. In AL, however, a monoclonal plasma cell population produces an abundance of a pathogenic LC protein. In this case, not all of the LCs pair with the HCs, and free LCs are secreted into circulation. The LC-HC dimer is very stable, and losing this interaction may result in an unstable LC protein [2]. Additionally, somatic mutations are thought to cause amyloidogenic proteins to be less stable compared to non-amyloidogenic proteins [3-5], leading to protein misfolding and amyloid fibril formation. The amyloid fibrils cause tissue damage and cell death, leading to patient death within 12-18 months if left untreated [6]. Current therapies are harsh and not curative, including chemotherapy and autologous stem cell transplants. Studies of protein pathogenesis and fibril formation mechanisms may lead to better therapies with an improved outlook for patient survival. Much has been done to determine the molecular factors that make a particular LC protein amyloidogenic and to elucidate the mechanism of amyloid fibril formation. Anthony Fink's work, particularly with discerning the role of intermediates in the fibril formation pathway, has made a remarkable impact in the field of amyloidosis research. This review provides a general overview of the current state of AL research and also attempts to capture the most recent ideas and knowledge generated from the Fink laboratory.

AB - Systemic light chain amyloidosis (AL) is one of several protein misfolding diseases and is characterized by extracellular deposition of immunoglobulin light chains in the form of amyloid fibrils [1]. Immunoglobulin (Ig) proteins consist of two light chains (LCs) and two heavy chains (HCs) that ordinarily form a heterotetramer which is secreted by a plasma cell. In AL, however, a monoclonal plasma cell population produces an abundance of a pathogenic LC protein. In this case, not all of the LCs pair with the HCs, and free LCs are secreted into circulation. The LC-HC dimer is very stable, and losing this interaction may result in an unstable LC protein [2]. Additionally, somatic mutations are thought to cause amyloidogenic proteins to be less stable compared to non-amyloidogenic proteins [3-5], leading to protein misfolding and amyloid fibril formation. The amyloid fibrils cause tissue damage and cell death, leading to patient death within 12-18 months if left untreated [6]. Current therapies are harsh and not curative, including chemotherapy and autologous stem cell transplants. Studies of protein pathogenesis and fibril formation mechanisms may lead to better therapies with an improved outlook for patient survival. Much has been done to determine the molecular factors that make a particular LC protein amyloidogenic and to elucidate the mechanism of amyloid fibril formation. Anthony Fink's work, particularly with discerning the role of intermediates in the fibril formation pathway, has made a remarkable impact in the field of amyloidosis research. This review provides a general overview of the current state of AL research and also attempts to capture the most recent ideas and knowledge generated from the Fink laboratory.

KW - Amyloid

KW - Fibril formation

KW - Immunoglobulin light chain

KW - Light chain amyloidosis

KW - Protein misfolding

UR - http://www.scopus.com/inward/record.url?scp=70349490011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349490011&partnerID=8YFLogxK

U2 - 10.2174/138920309789351949

DO - 10.2174/138920309789351949

M3 - Article

C2 - 19538145

AN - SCOPUS:70349490011

VL - 10

SP - 500

EP - 508

JO - Current Protein and Peptide Science

JF - Current Protein and Peptide Science

SN - 1389-2037

IS - 5

ER -